FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2884356747> ?p ?o ?g. }

• W2884356747 abstract "Adalimumab, a biological treatment targeting tumour necrosis factor α, might be useful in sciatica. This paper describes the challenges faced when developing a new treatment pathway for a randomised controlled trial of adalimumab for people with sciatica, as well as the reasons why the trial discussed was stopped early.A pragmatic, parallel group, randomised controlled trial with blinded (masked) participants, clinicians, outcome assessment and statistical analysis was conducted in six UK sites. Participants were identified and recruited from general practices, musculoskeletal services and outpatient physiotherapy clinics. They were adults with persistent symptoms of sciatica of 1 to 6 months' duration with moderate to high level of disability. Eligibility was assessed by research physiotherapists according to clinical criteria, and participants were randomised to receive two doses of adalimumab (80 mg then 40 mg 2 weeks later) or saline placebo subcutaneous injections in the posterior lateral thigh. Both groups were referred for a course of physiotherapy. Outcomes were measured at baseline, 6-week, 6-month and 12-month follow-up. The main outcome measure was disability measured using the Oswestry Disability Index. The planned sample size was 332, with the first 50 in an internal pilot phase.The internal pilot phase was discontinued after 10 months from opening owing to low recruitment (two of the six sites active, eight participants recruited). There were several challenges: contractual delays; one site did not complete contract negotiations, and two sites signed contracts shortly before trial closure; site withdrawal owing to patient safety concerns; difficulties obtaining excess treatment costs; and in the two sites that did recruit, recruitment was slower than planned because of operational issues and low uptake by potential participants.Improved patient care requires robust clinical research within contexts in which treatments can realistically be provided. Step changes in treatment, such as the introduction of biologic treatments for severe sciatica, raise complex issues that can delay trial initiation and retard recruitment. Additional preparatory work might be required before testing novel treatments. A randomised controlled trial of tumour necrosis factor-α blockade is still needed to determine its cost-effectiveness in severe sciatica.Current Controlled Trials, ISRCTN14569274 . Registered on 15 December 2014." @default.
• W2884356747 created "2018-08-03" @default.
• W2884356747 creator A5003432782 @default.
• W2884356747 creator A5008042220 @default.
• W2884356747 creator A5014720616 @default.
• W2884356747 creator A5015068573 @default.
• W2884356747 creator A5016047388 @default.
• W2884356747 creator A5018168225 @default.
• W2884356747 creator A5031453176 @default.
• W2884356747 creator A5032813108 @default.
• W2884356747 creator A5046396554 @default.
• W2884356747 creator A5068179853 @default.
• W2884356747 creator A5070376982 @default.
• W2884356747 creator A5071753812 @default.
• W2884356747 creator A5075175960 @default.
• W2884356747 creator A5081923835 @default.
• W2884356747 creator A5085893592 @default.
• W2884356747 creator A5088964555 @default.
• W2884356747 creator A5090692961 @default.
• W2884356747 date "2018-07-31" @default.
• W2884356747 modified "2023-10-14" @default.
• W2884356747 title "Lessons learnt from a discontinued randomised controlled trial: adalimumab injection compared with placebo for patients receiving physiotherapy treatment for sciatica (Subcutaneous Injection of Adalimumab Trial compared with Control: SCIATiC)" @default.
• W2884356747 cites W1531353720 @default.
• W2884356747 cites W1818428811 @default.
• W2884356747 cites W1845447069 @default.
• W2884356747 cites W1967665781 @default.
• W2884356747 cites W1968697017 @default.
• W2884356747 cites W1980698128 @default.
• W2884356747 cites W1992027756 @default.
• W2884356747 cites W2021865356 @default.
• W2884356747 cites W2041609060 @default.
• W2884356747 cites W2043903477 @default.
• W2884356747 cites W2058950159 @default.
• W2884356747 cites W2062081863 @default.
• W2884356747 cites W2062443774 @default.
• W2884356747 cites W2067435956 @default.
• W2884356747 cites W2067804071 @default.
• W2884356747 cites W2075547289 @default.
• W2884356747 cites W2077554908 @default.
• W2884356747 cites W2080715613 @default.
• W2884356747 cites W2088628410 @default.
• W2884356747 cites W2093320900 @default.
• W2884356747 cites W2096218277 @default.
• W2884356747 cites W2097351750 @default.
• W2884356747 cites W2102725242 @default.
• W2884356747 cites W2110112325 @default.
• W2884356747 cites W2118516436 @default.
• W2884356747 cites W2122306415 @default.
• W2884356747 cites W2129530569 @default.
• W2884356747 cites W2130286386 @default.
• W2884356747 cites W2133124363 @default.
• W2884356747 cites W2133751887 @default.
• W2884356747 cites W2139785602 @default.
• W2884356747 cites W2141832642 @default.
• W2884356747 cites W2165263345 @default.
• W2884356747 cites W2166281097 @default.
• W2884356747 cites W2172252002 @default.
• W2884356747 cites W2414442728 @default.
• W2884356747 cites W2473786944 @default.
• W2884356747 cites W2607807617 @default.
• W2884356747 cites W2738311207 @default.
• W2884356747 cites W2747515651 @default.
• W2884356747 cites W3082030516 @default.
• W2884356747 doi "https://doi.org/10.1186/s13063-018-2801-6" @default.
• W2884356747 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/6069989" @default.
• W2884356747 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/30064491" @default.
• W2884356747 hasPublicationYear "2018" @default.
• W2884356747 type Work @default.
• W2884356747 sameAs 2884356747 @default.
• W2884356747 citedByCount "1" @default.
• W2884356747 countsByYear W28843567472020 @default.
• W2884356747 crossrefType "journal-article" @default.
• W2884356747 hasAuthorship W2884356747A5003432782 @default.
• W2884356747 hasAuthorship W2884356747A5008042220 @default.
• W2884356747 hasAuthorship W2884356747A5014720616 @default.
• W2884356747 hasAuthorship W2884356747A5015068573 @default.
• W2884356747 hasAuthorship W2884356747A5016047388 @default.
• W2884356747 hasAuthorship W2884356747A5018168225 @default.
• W2884356747 hasAuthorship W2884356747A5031453176 @default.
• W2884356747 hasAuthorship W2884356747A5032813108 @default.
• W2884356747 hasAuthorship W2884356747A5046396554 @default.
• W2884356747 hasAuthorship W2884356747A5068179853 @default.
• W2884356747 hasAuthorship W2884356747A5070376982 @default.
• W2884356747 hasAuthorship W2884356747A5071753812 @default.
• W2884356747 hasAuthorship W2884356747A5075175960 @default.
• W2884356747 hasAuthorship W2884356747A5081923835 @default.
• W2884356747 hasAuthorship W2884356747A5085893592 @default.
• W2884356747 hasAuthorship W2884356747A5088964555 @default.
• W2884356747 hasAuthorship W2884356747A5090692961 @default.
• W2884356747 hasBestOaLocation W28843567471 @default.
• W2884356747 hasConcept C126322002 @default.
• W2884356747 hasConcept C141071460 @default.
• W2884356747 hasConcept C142724271 @default.
• W2884356747 hasConcept C168563851 @default.
• W2884356747 hasConcept C1862650 @default.
• W2884356747 hasConcept C204243189 @default.
• W2884356747 hasConcept C204787440 @default.
• W2884356747 hasConcept C27081682 @default.
• W2884356747 hasConcept C2776698514 @default.
• W2884356747 hasConcept C2779134260 @default.

• next